Article

Alprazolam in the treatment of anticipatory and acute situational anxiety in children with cancer

Houston Zoo, Houston, Texas, United States
Journal of the American Academy of Child & Adolescent Psychiatry (Impact Factor: 6.35). 08/1987; 26(4):532-5. DOI: 10.1097/00004583-198707000-00012
Source: PubMed

ABSTRACT A population of childhood cancer patients who undergo scheduled, periodic, stressful events such as bone marrow aspirations and spinal taps was chosen as a model for the investigation of the use of alprazolam in the treatment of anticipatory and acute situational anxiety in children. An open-label dose-ranging study was completed on 13 children. Because this was an early trial of a drug not approved for use in children, doses were low. Nonetheless, safe efficacious use of alprazolam was demonstrated and indicates that antianxiety agents may have a useful purpose for brief intervention situations in children.

0 Followers
 · 
59 Views
 · 
0 Downloads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The GABA/benzodiazepine receptor chloride channel complex has been proposed to play a modulatory role in immune function. The effects of alprazolam, a triazolobenzodiazepine with high affinity for "central" benzodiazepine receptors, were examined on several parameters of immune function in mice. Natural killer cell activity, mixed leukocyte reactivity and mitogen-induced lymphocyte proliferation were all significantly increased two hr after administration of low doses (0.02-1.0 mg/kg) of alprazolam. Twenty four hr later, similar but less robust immunoenhancing effects were observed. Higher doses of alprazolam (5-10 mg/kg) did not affect these measures of immune function. The immunoenhancing effects of alprazolam did not appear related to corticosterone levels. In contrast, vehicle injection caused a profound suppression of these immune parameters two hr later, which was no longer apparent 24 hr later. This immunosuppression appeared to correlate with a concurrent rise in serum corticosterone levels. These data support the hypothesis that the GABA/benzodiazepine receptor chloride channel complex modulates immune function. Use of low doses of alprazolam may be of potential clinical importance when immunoenhancement is required.
    Life Sciences 02/1990; 47(26):2409-20. DOI:10.1016/0024-3205(90)90485-A · 2.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The 1980s were a decade of advancement in the knowledge of anxiety disorders in children and adolescents; this sets the stage for research achievements in the 1990s. This review examines the anxiety disorders of childhood and adolescence (separation anxiety disorder, overanxious disorder, and avoidant disorder), including prevalence rates, demographic profiles, comparisons of clinical presentations in different developmental age groups, and comorbidity patterns. Fears and simple phobias, obsessive-compulsive disorder, post-traumatic stress disorder, and panic disorder in children and adolescents are also evaluated. The controversy of whether panic attacks occur in prepubertal children is addressed. A brief review of behavioral and pharmacological treatment studies is included. Future directions for research are suggested.
    Journal of the American Academy of Child & Adolescent Psychiatry 08/1991; 30(4):519-32. DOI:10.1097/00004583-199107000-00001 · 6.35 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the past 5 years, we have witnessed the continuation of important trends in clinical research that began earlier in the decade. With regard to the treatment of specific disorders in children and adolescents, the most significant developments have been the examination of the tricyclics for the treatment of depression and the initiation of controlled studies for the treatment of Tourette syndrome. Unfortunately, the findings from the depression studies have been uniformly negative, and the results of research on both depression and tic disorders show a relatively high rate of placebo responsivity, which raises nagging questions about the role of case reports and open trials. Another important trend in pediatric psychopharmacotherapy is the search for substitutes for the neuroleptics. Potential candidates include agents such as lithium, naltrexone, fenfluramine, clonidine, and carbamazepine. The most underresearched disorders are a combination of the least common (e.g. schizophrenia, mania) and those that are apparently perceived as less serious (e.g. sleep disorders, certain anxiety disorders). Not surprisingly, the most studied disorder and treatment is hyperactivity and stimulant medication, respectively. Considerable progress has been made in understanding the social implications of the associated symptoms and their response to stimulant drugs, aided greatly by the use of direct observation procedures. Researchers are beginning to attend to the implications of comorbidity for assessing response to medication. There has been additional confirmation of efficacy of stimulant treatment for preschoolers and adolescents. Dose-response issues remain to some extent unresolved, the primary impediments being interpretive misconceptions associated with trend analysis, an overreliance on the syndromal perspective and too little attention to target behaviors and their clinical implications, and the failure to operationalize the minimal effective dose with regard to the normalization and supranormalization of target and collateral behaviors. Disagreement over whether hyperactivity is a learning or a behavior disorder (or both) and what academic underproductivity means clinically and socially is also impeding progress. With regard to developmental disorders, controlled studies indicate that fenfluramine and naltrexone are effective for managing associated symptoms in some individuals. However, given the limited amount of research on these agents, their status as clinically useful palliatives must be considered tentative.(ABSTRACT TRUNCATED AT 400 WORDS)
    Journal of Child Psychology and Psychiatry 02/1992; 33(1):153-95. DOI:10.1111/j.1469-7610.1992.tb00861.x · 5.67 Impact Factor
Show more